

Special Issue

Treatment for HPV-Associated Cervical Cancer: Novel Therapeutic Strategies

Message from the Guest Editors

Despite progress in cervical cancer (CC) management, it remains a leading cause of mortality among women globally. Persistent challenges include HPV infections (notably types 16 and 18), limited screening access, low vaccination rates, insufficient awareness, and treatment resistance. Recent advances in biomarker discovery (e.g., proteomic, transcriptomic, miRNA, and lncRNA profiling) are refining diagnostics and enhancing treatment efficacy. Innovations such as targeted silencing, drug repositioning, and nanotechnology are driving the shift toward personalized and precision medicine. These strategies hold promise for reducing CC's global burden, particularly in low- and middle-income countries. This Special Issue invites submissions on novel strategies to improve conventional CC therapies, prioritizing high efficacy, reduced side effects, and better patient quality of life. We welcome original research and reviews on drug discovery, delivery systems, therapeutic innovations, and diagnostic advancements in cervical cancer.

Guest Editors

Prof. Dr. Berenice Illades-Aguar

Dr. Yazmín Gómez-Gómez

Dr. Marco Antonio Leyva-Vázquez

Prof. Dr. Jorge Organista-Nava

Dr. Olga Lilia Garibay-Cerdenares

Deadline for manuscript submissions

25 December 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/241725

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)